A Study of Armored CAR T Cells in People With Cancer

The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

Trial Details

NCT ID
NCT07783477
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • DLL3-SAVVYZ-IL18 CAR T cell
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Participant Inclusion: Collection of T cells (Part A)
  • History of DLL3+ neuroendocrine tumors
  • Includes patients with histologically confirmed SCLC, as well other advanced neuroendocrine tumors (NETs), including large cell neuroendocrine carc…
  • Any disease status is eligible for collection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →